context of multimodal analgesia and were not improved by additives. However, perineural buprenorphine and dexamethasone prolonged block duration, reduced the worst pain experienced, and reduced opioid use. Intravenous buprenorphine caused troubling nausea and vomiting. Future research is needed to confirm and extend these observations.
(Reg Anesth Pain Med 2015;40: 321-329) P rolongation of peripheral nerve block may reduce pain, opioid use, and opioid-related adverse effects. Sciatic nerve blocks in the popliteal fossa provide analgesia for about 14 hours; increasing the concentration of local anesthetic does not prolong the duration of analgesia. 1 Perineural clonidine prolongs duration of analgesia to approximately 18 hours. 2 A meta-analysis found that addition of dexamethasone to local anesthetics prolonged brachial plexus blockade. 3 However, recent studies using systemic dexamethasone controls failed to show major benefits from perineural dexamethasone. [4] [5] [6] Systemic dexamethasone provides analgesia when used at more than 0.1 mg/kg, 7 emphasizing the need for systemic controls. Pain scores after bupivacaine sciatic nerve block were improved by buprenorphine, a partial μ-opioid agonist, administered either perineural or intramuscular. 8 After sciatic block, perineural buprenorphine provided longer duration of analgesia than did intramuscular buprenorphine, judged both by pain scores and time until additional opioid analgesic administration. Buprenorphine also prolongs the duration of analgesia after axillary nerve blockade, 9 subclavian perivascular brachial plexus block, 10 and intraoral nerve blockade. 11 Addition of multiple adjuvants to local anesthetic ("multimodal perineural analgesia") may prolong analgesia after singleinjection peripheral nerve blockade. 12 We hypothesized that addition of dexamethasone and buprenorphine to a bupivacaine sciatic nerve block in the popliteal fossa, in the context of multimodal analgesia, would improve analgesia, specifically by reducing pain scores at 24 hours.
METHODS
After approval from Hospital for Special Surgery's institutional review board and informed written consent was obtained, 90 patients (aged 18-75 years) scheduled for discharge after foot or ankle surgery (with one of 2 coinvestigator surgeons) with planned use of spinal anesthesia and sciatic nerve blockade entered the study (Fig. 1) . Common reasons for exclusion were no popliteal block planned (n = 170), no research staff available for follow-up (n = 74), and planned admission for postoperative intravenous (IV) opioid analgesia (n = 27). This study was registered at ClinicalTrials.gov, NCT02198235.
Exclusion criteria follow: surgery that would cause significant pain at sites outside the distal lower extremity (eg, iliac crest bone graft was an exclusion criterion, but iliac crest bone marrow aspiration was not grounds for exclusion), bilateral surgery, regular use of opioid analgesics for more than 3 months, regular use of steroids for more than 3 months, contraindication to performance of the popliteal fossa nerve block with 0.25% bupivacaine (eg, alleged bupivacaine sensitivity, low body weight), contraindications to dexamethasone or buprenorphine (eg, allergy, insulindependent diabetes mellitus), altered pain perception or lack of sensation in the operative leg, inability of the patient to describe postoperative pain (eg, psychiatric disorder, dementia), nonEnglish-speaking patients (questionnaires were in English).
Prior to study start, a research assistant not otherwise associated with the study prepared opaque numbered envelopes containing group assignment; each envelope was opened after the patient signed consent. Blocked randomization with a blocking factor of 2 was used. This was a parallel 1:1:1 ratio study, conducted at an orthopedic teaching hospital. The intraoperative anesthesiologist was not blinded to group assignment, but the patient and the research assistant collecting the data were both blinded. All patients received a sciatic and an adductor canal block with 0.25% bupivacaine. Sciatic nerve block (25 mL) in the popliteal fossa was performed with the patient prone, using ultrasound guidance. The nerves were traced to the level immediately proximal to the union of the tibial and peroneal branches. A 22-gauge, 102-mm Chiba needle (Hakko Co Ltd, Tokyo, Japan) was introduced, in-plane from the lateral side, to pierce the fascia surrounding the 2 nerve bundles. Local anesthetic was injected between the bundles, with the goal of separating, but not injecting into, the nerve bundles. This nerve block can be described as subparaneural, 13 intraneural but extrafascicular, 14 or paraneural. 15 Ultrasound-guided adductor canal blockade was performed 6 to 8 cm above the knee, using 10 mL of the same solution used for the sciatic block.
Patients were randomized to 1 of 3 groups (n = 30/group): (1) control nerve blocks + IV dexamethasone (4 mg) ("IV dexamethasone"); (2) control nerve blocks + IV buprenorphine (150 μg) + IV dexamethasone (4 mg) ("IV buprenorphine + dexamethasone"); and (3) nerve blocks containing buprenorphine (150 μg) + dexamethasone (4 mg) ("perineural buprenorphine + dexamethasone"). Perineural buprenorphine and dexamethasone represent "off-label" usage, but as discussed in other articles, perineural use is described in multiple textbooks and publications. 8, 16 Patients received a standardized anesthetic and analgesic protocol. Intravenous sedation was provided with midazolam and propofol (no opioids, no ketamine). Neuraxial anesthesia was performed (spinal or combined spinal-epidural) with 60 mg subarachnoid mepivacaine. Epidural 2% lidocaine (5-10 mL at a time) was used as needed to maintain intraoperative blockade. Intravenous intraoperative medications included famotidine (20 mg), ondansetron (4 mg), and ketorolac (30 mg, reduced to 15 mg if <60 kg or >70 years old).
Postoperative medications included oxycodone/acetaminophen (5 mg/325 mg) 1 to 2 orally every 4 hours as needed, meloxicam 15 mg orally every night at bedtime (postoperative day 0, 1 [POD0, 1], reduced to 7.5 mg if >70 years old), pregabalin 50 mg orally every night at bedtime for 5 days, and ondansetron 8 mg orally every day as needed for nausea.
The primary outcome was pain with movement at 24 hours from the nerve block (numerical rating scale "When did the nerve block stop providing pain relief?" "When did you first need to take a pain pill?" and "When did the nerve block entirely wear off?" Additional outcome measures included opioid usage (PACU, 24 hours, 48 hours), Opioid-Related Symptom Distress Scale (24 hours), 18 and quality of sleep (assessed for the first 2 postoperative nights). Block-related complications were assessed at 1 month by asking if there were postprocedural impaired movement or sensation on the operative leg. Study data were collected and managed using REDCap electronic data capture tools hosted at Hospital for Special Surgery. 19 REDCap (Research Electronic Data Capture) is a secure, Web-based application to support data capture for research studies.
Data were analyzed after 15 patients per group. Study discontinuation was planned if patients in a group had pain at 24 hours that statistically significantly exceeded pain in the IV dexamethasone group by 2 units. The stopping criteria were not met (Hedden J, Goon A, Swamy L, et al. Addition of dexamethasone and buprenorphine to bupivacaine for sciatic nerve blockade: a prospective, blinded, randomized controlled trial. Presented at the 39th Annual Regional Anesthesiology and Acute Pain Medicine Meeting; Chicago, Illinois; 2014: ASRA1-0146), so the study was completed as designed.
A sample size of 27 patients in each of 3 treatment groups would provide 80% power at a 2-sided α level of 0.05 to detect a 1.5-point difference in NRS pain score with movement (3.2 vs 1.7 with common within-group SD of 1. 9 20 ) between the control (IV dexamethasone) and each experimental group (IV buprenorphine + dexamethasone and perineural buprenorphine + dexamethasone) using pairwise independent-samples t tests. Assuming a 10% dropout rate, we planned to enroll 30 patients per group for a total of 90 patients in the study.
Non-normally distributed ordinal outcomes are reported as both means with SDs and medians with first and third quartiles and compared between the control and each experimental group using Fisher-Pitman permutation tests. 21 This nonparametric test involves calculating the t test statistic for all possible permutations of group labels among data from pairs of treatment arms and comparing the observed t statistic to the distribution of t statistics from all permutations. Normality of continuous variables was assessed via histograms, quantile-quantile plots, and Shapiro-Wilk tests. The generalized estimating equation (GEE) method 22, 23 with an autoregressive (AR [1] ) correlation structure was used to compare NRS pain score between groups in the PACU and at 24 hours and 48 hours after adjustment for holding area score. Binary outcomes are presented as risk difference and relative risk with respect to the control group and compared using χ 2 or Fisher exact tests, as appropriate. The Kaplan-Meier method was used to calculate the median and 95% confidence intervals (CIs; log-log transformation) for time-to-event outcomes in the presence of censored data. Hazard ratios were obtained via Cox proportional hazards models. All statistical tests were 2-sided with a P < 0.05 considered statistically significant. Adjustment for multiple comparisons was not performed because each of the experimental group/control group comparisons was defined a priori. Statistical analyses were performed with SAS version 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
Ninety patients were enrolled (Fig. 1, Table 1 ), from October 2012 to January 2014. The primary end point was analyzed in 83 patients (Fig. 1 ). Patient characteristics are described in Table 1 . The epidural was dosed in 11 of 90 patients.
There was no evidence of a difference in the primary outcome of pain with movement at 24 hours between either the IV buprenorphine + dexamethasone group ASA indicates American Society of Anesthesiologists physical status classification system; BMI, body mass index; IV dexamethasone, control nerve blocks + IV dexamethasone (4 mg); IV buprenorphine + dexamethasone, control nerve blocks + IV buprenorphine (150 μg) + IV dexamethasone (4 mg); perineural buprenorphine + dexamethasone, nerve blocks containing buprenorphine (150 μg) + dexamethasone (4 mg); ORIF, open reduction internal fixation.
dexamethasone group (P = 0.149 and 0.390, respectively) (Fig. 2) . There was evidence of lack of normality for NRS pain scores at rest and with movement (Shapiro-Wilk tests P < 0.05). Histograms and quantile-quantile plots of residuals revealed positively skewed data. Pain scores were presented as median (Q1, Q3), but for reference, mean ± SD scores (24 hours' NRS with movement) were 1.9 ± 2.6 (IV dexamethasone), 1.0 ± 1.6 (IV buprenorphine + dexamethasone), and 1.3 ± 2.1 (perineural buprenorphine + dexamethasone). Longitudinal modeling of NRS pain with movement with adjustment for preoperative score via the GEE method also did not show a difference between IV buprenorphine + dexamethasone and IV dexamethasone or between perineural buprenorphine + dexamethasone and IV dexamethasone at 24 hours ( Table 2) .
The median (Q1, Q3) pain with movement was 0 (0, 0) for all groups on the day of surgery after resolution of the spinal and rose to 4 (0, 6), 4 (2, 5), and 4 (3, 6) in the IV dexamethasone, IV buprenorphine + dexamethasone, and perineural buprenorphine + dexamethasone groups, respectively, by 48 hours (Table 2 ). Pain at rest followed a similar pattern, but with lower magnitude of pain (Table 2) . No difference between groups in pain with movement or at rest was found via GEE analysis on the day of surgery after resolution of the spinal, 24 hours, or 48 hours (Table 2) .
Brief Pain Inventory worst pain favored administration of buprenorphine, both IV and perineural (Table 2) . Median satisfaction score was 10 (Q1, Q3: 9, 10) for all groups. There were no unexpected spontaneously reported adverse events at 24 hours; answers focused on opioid use, pain location, and persistent numbness.
The median (95% CI) time to block regression (for the question "When did the nerve block entirely wear off?") was 30.0 hours (24.1-45.2) for IV dexamethasone, 37.9 hours (30.7-43.9) for IV buprenorphine + dexamethasone, and 45.6 hours (33.9-53.8) for perineural buprenorphine + dexamethasone (Fig. 3) . There Other block duration questions did not achieve statistical significance (Table 3) . The percentage of patients needing opioids in the first 24 hours was lower for patients receiving buprenorphine: 60.7% of IV dexamethasone patients needed opioids versus 28.6% for IV buprenorphine + dexamethasone, 28.6% for perineural buprenorphine + dexamethasone (difference [95% CI]: 32% [6.1-52.8]; P = 0.016) ( Table 4) . Nausea in the PACU was noted with IV buprenorphine + dexamethasone, but not with perineural buprenorphine + dexamethasone (Table 4) . Patients in the IV buprenorphine + dexamethasone group demonstrated higher rates of nausea and vomiting at 24 hours as compared with IV dexamethasone (Table 4) . Patients in the perineural buprenorphine + dexamethasone group did not have higher rates of nausea and vomiting compared with IV dexamethasone. Other Opioid-Related Symptom Distress Scale data also indicated increased distress in the IV buprenorphine + dexamethasone group (Table 4) .
Difficulty sleeping POD1 was uncommon: 2 of 21 (IV dexamethasone), 0 of 27 (IV buprenorphine + dexamethasone), and 2 of 28 (perineural buprenorphine + dexamethasone). At POD30 phone call, 2 patients commented on numbness. One patient (IV buprenorphine + dexamethasone) had decreased sensation at the surgical scar. One patient (perineural buprenorphine + dexamethasone) reported that "part of foot feels a little bit numb" but was not more specific. When this patient returned to the surgeon's office Time to event calculated from end of block administration to patient report of event. Data were censored at the time of last interview if the event did not occur during the assessment period.
IV dexamethasone indicates control nerve blocks + IV dexamethasone (4 mg); IV buprenorphine + dexamethasone, control nerve blocks + IV buprenorphine (150 μg) + IV dexamethasone (4 mg); perineural buprenorphine + dexamethasone, nerve blocks containing buprenorphine (150 μg) + dexamethasone (4 mg). at 6 months, the symptoms were entirely resolved. Two patients (both in IV dexamethasone) reported uncomfortable swollen operative feet.
DISCUSSION
Addition of buprenorphine and dexamethasone to bupivacaine for sciatic nerve blockade in the popliteal fossa did not improve pain with movement at 24 hours. Pain scores at 24 hours were low; median scores were 0 in all 3 groups, suggesting that attempts to improve pain at 24 hours are unlikely to succeed. Previous work at the authors' institution found that duration of analgesia after sciatic nerve blockade lasted 14 to 18 hours. 1, 2, 20 The power analysis (based on previous work 20 ) assumed NRS means of 3.2 (control) versus 1.7 (experimental); observed mean pain scores at 24 hours were lower (1.9 and 1.3, respectively), with median pain scores of 0. Low pain scores may be attributable to the multimodal analgesic regimen of neuraxial anesthesia, nerve blockade, nonsteroidal anti-inflammatory, pregabalin, acetaminophen, and opioids. In addition, the use of a subparaneural injection site 24 prolongs duration of analgesia from a sciatic nerve block in the popliteal fossa.
Some secondary outcomes suggest beneficial aspects of perineural buprenorphine/dexamethasone. The perineural buprenorphine + dexamethasone group experienced longer block duration than did the IV dexamethasone group (45.6 vs 30.0 hours) and was spared the nausea prominently associated with IV buprenorphine + dexamethasone on POD1 (19.2% vs 57.7%). Patients in the perineural buprenorphine + dexamethasone group had lower scores for "worst pain" compared with IV dexamethasone (mean of 1.6 vs 3.4). Both experimental groups (IV buprenorphine + dexamethasone and perineural buprenorphine + dexamethasone) were less likely to use additional opioids in the first day after surgery, compared with IV dexamethasone (28.6%, 28.6%, and 60.7%, respectively). Preoperative administration of either IV or perineural buprenorphine, a potent opioid, is expected to reduce postoperative consumption of additional opioids. The mean duration of pain relief from 0.2 mg intramuscular buprenorphine is 5.6 hours. 25 It is unproven that these differences (longer block duration, lower "worst pain," and decreased use of additional opioids) represent clinically significant value.
Nausea after IV buprenorphine + dexamethasone was often severe, frequent, and bothersome, despite prophylactic and ondemand antiemetics. Because of the high impact of nausea and the low yield of analgesia, IV buprenorphine should be avoided in this patient population. Addition of buprenorphine to the nerve block did not cause increased or extensive nausea and vomiting.
Use of dexamethasone as an adjunct for peripheral nerve blockade remains controversial, despite extensive recent study. Low-dose dexamethasone had no effect on in vitro ropivacaineinduced toxicity following a 24-hour exposure, but higher doses increased rates of neuron cell death. 26 On the other hand, a different in vitro model system found dexamethasone protective against bupivacaine-induced neuron injury. 27 It has been suggested that these in vitro data need to be viewed critically and that perhaps the use of prolonged infusions of ropivacaine via perineural catheters should be reevaluated. 28 Some clinical studies that found benefit of perineural dexamethasone lack systemic controls. 3 Three recent studies that question the benefit of perineural dexamethasone (compared with IV control) present interesting methodological issues. One 6 found that perineural dexamethasone (8 mg) did not improve Quality of Recovery 40. However, perineural dexamethasone prolonged analgesia (compared with both saline and IV controls) and reduced pain on POD1. Another 5 found that perineural dexamethasone (8 mg, combined with 8 mg IV; total dose 16 mg) did not reduce pain at 48 hours, the primary outcome. However, sciatic perineural dexamethasone reduced pain for the first 24 hours. Third, 4 perineural dexamethasone (10 mg) did not reduce time to analgesic use, compared with systemic dexamethasone (1405 vs 1275 minutes), but it was suggested that the study was underpowered for this comparison. 29 All of these studies used dexamethasone doses (8, 10, 16 mg) that were higher than those used in this study (4 mg). Systemic dexamethasone doses greater than 0.1 mg/kg (as used in these 3 studies) are expected to have analgesic effects. 7 A meta-analysis indicates that the 4-mg dose used in the current study is not expected to have major systemic analgesic effect 7 ; however, this population-based statement would not necessarily apply to each patient.
Buprenorphine has been extensively studied as an adjunct for peripheral nerve blockade. [8] [9] [10] [11] 28 Clinical concentrations of buprenorphine had no effect on in vitro ropivacaine-induced toxicity following a 24-hour exposure. 26 Buprenorphine, both perineural and intramuscular, improved analgesia after bupivacaine sciatic nerve blockade. 8 Compared with control, perineural buprenorphine prolonged analgesia (from 6-12 hours to 24-36 hours), with decreased opioid use in the first 12 hours at home (from about 6 mg to about 2 mg hydrocodone). 8 Similarly, in this study, combined perineural administration of dexamethasone and buprenorphine (compared with control) prolonged analgesia (from 30 to 45.6 hours), reduced worst pain score (from 2 to 0), and decreased use of additional opioids on POD1 (from 60.7% of patients to 32.1%). Study differences include the primary anesthetic, use of ultrasound, prophylactic antiemetics, and multimodal analgesia.
Safety data about combinations of local anesthetic and combined adjuncts are limited. A recent laboratory study with a similar drug combination (bupivacaine, clonidine, buprenorphine, dexamethasone) demonstrated both in vivo safety (ie, absence of any test article-related changes in nerves after sciatic nerve blockade in rats) and in vitro chemical compatibility and stability. 30 In addition, quality assurance data are available after administration of combined multiple additives for nerve blockade in more than 1300 clinical cases. 31 Strengths of the study include use of a randomized controlled trial design, including a systemic control group. Systemic controls were used for dexamethasone and buprenorphine. Numerous outcomes were measured (following IMMPACT guidelines as applied to acute pain studies), covering pain, use of analgesics, physical functioning, satisfaction, symptoms and adverse events, and participant disposition. 17 Weaknesses of the study include the assumption of higher pain scores at 24 hours for the power analysis. Pain scores at 24 hours were substantially lower than predicted, and no difference was seen between groups at 24 hours. The study examined the concept of multimodal perineural analgesia, so it is not possible to determine whether the effects were due to buprenorphine, dexamethasone, or the combination. Different doses or combinations of the adjuvants may have different effects. All 3 groups received 4 mg dexamethasone; an additional control group that did not receive dexamethasone would have helped clarify the analgesic role of systemic dexamethasone. Both IV and perineural study drugs were administered intraoperatively to sedated patients by unblinded physicians; data collection was performed by blinded researchers. Blinding could potentially have been improved by remote preparation of study drugs and blinding of study physicians.
Further research is needed to confirm that perineural buprenorphine and dexamethasone (1) reduce the worst pain experienced, (2) prolong time until block resolution, and (3) reduce need for postoperative opioids. Before recommending use of these additives, it would be necessary to demonstrate clinically meaningful benefit. Studies are needed to assess whether both buprenorphine and dexamethasone are needed, and if so, in which combination. Large-scale clinical trials are needed to evaluate safety. Direct comparison of safety and efficacy of perineural catheters versus single-injection nerve blockade with additives would be of interest.
In conclusion, median pain scores were zero at 24 hours after foot and ankle surgery in the context of a multimodal analgesic and were not improved by either perineural or IV administration of buprenorphine, 150 μg, and dexamethasone, 4 mg. Perineural buprenorphine and dexamethasone reduced the worst pain experienced, prolonged block duration, and reduced postoperative opioid use. Intravenous buprenorphine caused troubling nausea and vomiting, despite antiemetics. Future research is needed to confirm and extend these observations.
